Detail akcie AIxCrypto Holdings, Inc online

Business Summary: AIxCrypto Holdings, Inc., formerly Qualigen Therapeutics, Inc., is focused on building an ecosystem that integrates Artificial Intelligence (AI) and blockchain, bridging Web2 and Web3. This ecosystem unites a decentralized protocol, distributed network, AI DePIN and EAI RWA value regeneration, and a DeAI Agent product and technology platform designed to achieve optimal trading performance. Its core products include the BesTrade DeAI Agent and the AIxC ecosystem products. Its crypto business, CXC10, is centered on three growth engines which include six key products: C - Crypto 10 (C10) as Value Anchor, X - DeAI Agent, and C - RWA & Ecosystem Tokens. C - Crypto 10 (C10) as Value Anchor - through the C10 Digital Asset Treasury, C10 Index, and a potential C10 ETF. C - RWA & Ecosystem Tokens - including the C10 Stablecoin and the EAI + Crypto Dual-Bridge Real World Asset product, bridging traditional assets with Web3. It also develops and commercializes oncology and immunology therapies.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Aixcrypto Holdings Inc revenues was not reported. Net loss applicable to common stockholders excluding extraordinary items increased 34% to $7.2M. Higher net loss reflects PHARMACEUTICALS segment loss increase of 32% to $5.8M, United States segment loss increase of 32% to $5.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$32.01 to -$7.50.